As per current monthly report, the Central Drugs Standards Control Organisation (CDSCO) labelled over fifty medications as not of standard quality, raising worries about their use and safety. These medications included paracetamol, Pan D, and other calcium supplements.
The government drug authority declared paracetamol, calcium and vitamin D supplements, blood pressure drugs, and some anti-diabetes tablets as “Not of Standard Quality (NSQ Alert)” in its August 2024 report. State drug officers randomly sample the population each month to create NSQ notifications. The anti-diabetic pharmaceutical Glimepiride, the vitamin C and D3 pills, Shelcal, the vitamin B complex, the vitamin C softgels, the anti-acid Pan-D and the IP 500 mg paracetamol tablets are among the medications that did not pass the quality inspection.
Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), Karnataka Antibiotics & Pharmaceuticals Ltd, Pure & Cure Healthcare, and Meg Lifesciences were a few of the companies that produced these goods. Quality testing also revealed that metronidazole, a medication used frequently to treat stomach infections caused by HAL, did not pass.
Shelcal, a well-known supplement containing calcium and vitamin D3, has also been labelled in the NSQ Alert category. Around 156 fixed-dose medication combinations were outlawed nationwide by the CDSCO in August of this year due to possible human health risks.